Standard & Poor’s has affirmed its ‘A-‘ counterparty credit and financial strength ratings and negative outlook on Amedex Insurance Co.
Standard & Poor’s subsequently withdrew the ratings at the company’s request. The ratings reflected Amedex’s good business position as a niche provider of major medical products in Latin America, favorable operating performance, and strong capitalization.
These positive factors are offset by Amedex’s limited size, declining enrollment trends, new business risk through Amedex Bermuda, and high operating expenses, which are the direct consequence of its target market and high level of service provided.
Was this article valuable?
Here are more articles you may enjoy.
Portugal Rolls Out $2.9 Billion Aid as Deadly Flooding Spreads
UBS Top Executives to Appear at Senate Hearing on Credit Suisse Nazi Accounts
Tesla Sued Over Crash That Trapped, Killed Massachusetts Driver
Why 2026 Is The Tipping Point for The Evolving Role of AI in Law and Claims